Chemo/Phototherapy of Cancer using Camptothecin Supported on CuFe2O4 (CPT@CuFe₂O₄) for Improvement of Chemo-Dynamic Therapy
نویسندگان
1 Tashkent State Medical University, Tashkent, Republic of Uzbekistan
2 Department of Otorhinolaryngology, Andijan State Medical Institute, Andijan, Republic of Uzbekistan
3 Tashkent State Technical University, Tashkent, Republic of Uzbekistan
4 Department of Oncology, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Republic of Uzbekistan
5 Department of Pharmacology, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Republic of Uzbekistan
6 Department of Orthopedist Dentistry va Orthodontics, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Republic of Uzbekistan
7 Department of Histology, Cytology and Embryology, Samarkand State Medical University, Samarkand, Republic of Uzbekistan
8 Department of Clinical Sciences, Mamun University, Urgench, Republic of Uzbekistan
9 Department of Medicine, Turon University, Karshi, Republic of Uzbekistan
10 Department of Oncology, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Republic of Uzbekistan
11 Samarkand Institute of Economics and Service, Samarkand, Republic of Uzbekistan
12 Samarkand Institute of Economics and Service, Samarkand, Republic of Uzbekistan
13 Department of “Medical and bilogical chemistry”, Ferghana medical institute of public health, Ferghana, Republic of Uzbekistan
doi
10.22052/JNS.2026.01.076چکیده
We report a rationally designed theranostic nanoplatform that integrates chemotherapy, photothermal therapy (PTT), and photo-enhanced chemodynamic therapy (CDT) in a single CPT@CuFe2O4 nanohybrid. Camptothecin (CPT), a hydrophobic topoisomerase I inhibitor, is non-covalently loaded onto CuFe2O4 spinel nanoparticles, yielding a core–shell–like construct that preserves the CuFe2O4 spinel framework while presenting an amorphous CPT surface layer. Comprehensive characterization (FE-SEM, FT-IR, XRD) confirms preserved crystallinity of the CuFe2O4 core and successful CPT incorporation without deleterious phase changes or CPT crystallization. The system exploits a triple-action mechanism: (i) CPT provides targeted chemotherapeutic cytotoxicity; (ii) CuFe2O4 serves as a robust near-infrared (NIR)–absorbing photothermal transducer (η ≈ 32.7%, ΔT up to ~55 °C at 100 μg/mL); and (iii) the CuFe2O4 core catalyzes Fenton-like reactions to generate hydroxyl radicals (•OH) from endogenous H2O2, with photothermal heating accelerating CDT (photo-enhanced CDT). In vitro experiments in MCF-7 cells reveal strong synergistic cytotoxicity under 808 nm irradiation (Bliss SI values 1.8–2.4), with complete triple-modal eradication observed at clinically relevant CPT/NP concentrations (∼100 μg/mL CPT-equivalent, 2 μM CPT). Collectively, CPT@CuFe2O4 demonstrates a potent, on-demand, multimodal cancer therapy platform that leverages localized photothermal heating to amplify endogenous CDT while delivering CPT at the tumor site. Potential translational relevance is discussed in the context of hypoxia-insensitive CDT and reduced systemic toxicity.
